Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus-positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies. Colevas, A., Rudek, M. A., Even, C., Lee, V., Gillison, M. L., Khan, S. A., Lu, R., Winters, E., Biedermann, S., Lai, S., Messick, T. LIPPINCOTT WILLIAMS & WILKINS. 2023

View details for Web of Science ID 001053772003156